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Abstract
Background: Late-onset Pompe disease is a rare genetic neuromuscular disorder caused by lysosomal acid alpha-
glucosidase (GAA) deficiency that ultimately results in mobility loss and respiratory failure. Current enzyme replacement
therapy with recombinant human (rh)GAA has demonstrated efficacy in subjects with late-onset Pompe disease.
However, long-term effects of rhGAA on pulmonary function have not been observed, likely related to inefficient
delivery of rhGAA to skeletal muscle lysosomes and associated deficits in the central nervous system. To address this
limitation, reveglucosidase alfa, a novel insulin-like growth factor 2 (IGF2)-tagged GAA analogue with improved
lysosomal uptake, was developed. This study evaluated the pharmacokinetics, safety, and exploratory efficacy of
reveglucosidase alfa in 22 subjects with late-onset Pompe disease who were previously untreated with rhGAA.
Results: Reveglucosidase alfa plasma concentrations increased linearly with dose, and the elimination half-life was <1.
2 h. Eighteen of 22 subjects completed 72 weeks of treatment. The most common adverse events were hypoglycemia
(63%), dizziness, fall, headache, and nausea (55% for each). Serious adverse events included hypersensitivity (n = 1),
symptomatic hypoglycemia (n = 2), presyncope (n = 1), and acute cardiac failure (n = 1). In the dose-escalation study,
all treated subjects tested positive for anti-reveglucosidase alfa, anti-rhGAA, anti-IGF1, and anti-IGF2 antibodies at least
once. Subjects receiving 20 mg/kg of reveglucosidase alfa demonstrated increases in predicted maximum inspiratory
pressure (13.9%), predicted maximum expiratory pressure (8.0%), forced vital capacity (−0.4%), maximum voluntary
ventilation (7.4 L/min), and mean absolute walking distance (22.3 m on the 6-min walk test) at 72 weeks.
Conclusions: Additional studies are needed to further assess the safety and efficacy of this approach. Improvements in
respiratory muscle strength, lung function, and walking endurance in subjects with LOPD may make up for the risk of
hypersensitivity reactions and hypoglycemia. Reveglucosidase alfa may provide a new treatment option for patients
with late-onset Pompe disease.
Trial registration: ISRCTN01435772 and ISRCTN01230801, registered 27 October 2011.
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Background
Late-onset Pompe disease (LOPD), a rare genetic
neuromuscular disorder, results in severe respiratory
dysfunction that often progresses to respiratory
failure [1]. LOPD is caused by a deficiency of the
lysosomal enzyme acid alpha glucosidase (GAA) [2],
which prevents enzymatic breakdown of glycogen. As
a result, glycogen accumulates in multiple tissues.
The most severe pathology in LOPD patients is
observed in skeletal muscles [3, 4]. Myopathy in
proximal skeletal muscles, for example, reduces
mobility in patients and eventually leads to loss of
independent ambulation [5]. Furthermore, weakness
of the respiratory muscles (eg, diaphragm) causes
respiratory dysfunction that initially manifests as
sleep-disordered breathing and nighttime hypercapnia
[6]. In more than 70% of patients, respiratory
dysfunction progresses to respiratory failure, which is
the most common cause of mortality in LOPD [7].
The early onset and progressive nature of the disease
highlight the need for safe and highly effective
treatments.
Recombinant human GAA (rhGAA), the first
enzyme replacement therapy (ERT) for LOPD,
became available in 2006 [8–11]. Although treatment
with rhGAA reduces mortality in infants with Pompe
disease, it provides limited improvements in mobility
and respiratory function [9, 12–14]. The uptake of
endogenous GAA into tissues is mediated by the
binding of bis-mannose 6-phosphorylated moieties on
GAA to the cation-independent mannose 6-
phosphate receptors (CI-MPR) in tissues [15]. How-
ever, rhGAA binds to the CI-MPR with low affinity
[16–18], which reduces uptake of the recombinant
enzyme into lysosomes.
To enhance the uptake of GAA into the lysosome,
a CI-MPR-targeting peptide—derived from insulin-
like growth factor 2 (IGF2)—was fused to GAA
to form the novel chimeric enzyme reveglucosidase
alfa (glycosylation-independent lysosomal targeting
[GILT]-tagged rhGAA). In preclinical models of
Pompe disease, reveglucosidase alfa is taken up by
skeletal muscle cells with greater efficiency than
rhGAA [15] and is more effective at reducing glyco-
gen in skeletal muscle [19]. The improved efficacy in
nonclinical models prompted an initial evaluation of
reveglucosidase alfa in LOPD subjects [19]. Here we
report the results of a first-in-human, phase 1/2,
open-label clinical trial that evaluated the pharmaco-
kinetics (PK), safety, tolerability, and efficacy of
reveglucosidase alfa in ambulatory LOPD subjects
who were naïve to prior ERT (ie, previously
untreated) and had mild-to-moderate respiratory
impairment.
Methods
Study design
This ongoing phase 1/2, international, multicenter,
open-label clinical trial of reveglucosidase alfa initially
enrolled subjects in a dose-escalation study (Clinical-
trials.gov identifier: NCT01230801; POM-001) [20]. Sub-
jects could then continue treatment in a dose-extension
study (Clinicaltrials.gov identifier: NCT01435772; POM-
002) [21]. POM-001 consisted of a 25-day pretreatment
screening period, a 3-day baseline and enrollment
period, a 24-week treatment period, and a provision to
continue participation in the dose-extension study. Fol-
lowing the screening and baseline assessments, subjects
were treated every 2 weeks for the 24-week treatment
period. After completion of POM-001, eligible subjects
continued reveglucosidase alfa treatment in POM-002
for additional 24-week treatment cycles (up to a max-
imum of twenty 24-week cycles, or 480 weeks). Local
review boards, ethics committees, and health authorities
at each of the 12 study centers approved the protocol
and all amendments. Informed consent was obtained
from each subject’s parent/guardian, and assent was
obtained from each subject where appropriate.
Subject selection
All eligible subjects had a confirmed diagnosis of LOPD
based on 2 GAA gene mutations and endogenous GAA
activity <75% of the lower limit of the normal adult
range. Additional inclusion criteria included age ≥ 13 years
at the time of study enrollment, predicted upright forced
vital capacity (FVC) ≥30%, and either predicted upright
FVC <80% or a reduction in supine FVC >10% com-
pared with upright FVC. Eligible subjects were naïve to
ERT with rhGAA (ie, previously untreated) and must
have been able to ambulate at least 40 m on the 6-min
walk test (6MWT). Subjects were excluded if they had
previously received any experimental or approved
therapy for LOPD prior to enrollment and had a medical
condition that, in the opinion of investigators, might
compromise the subject’s ability to comply with the
study protocol requirements.
Treatment
During the dose-escalation study (POM-001), subjects
were sequentially enrolled in 1 of 3 dosing regimens of
reveglucosidase alfa (5 mg/kg [n = 3], 10 mg/kg [n = 3],
and 20 mg/kg [n = 20] administered as an intravenous
infusion (of approximately 1.5–4 h’s duration) every
2 weeks during the 24-week treatment cycle. Interim
safety assessments were completed by an independent
review board prior to any dose escalation. POM-002, the
extension phase, enrolled subjects from POM-001 who
continued treatment at 5 mg/kg, 10 mg/kg, or 20 mg/kg
levels for additional treatment cycles. Treatment of
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patients was completed, and the analysis included data
for three 24-week treatment cycles (ie, 72 weeks of total
exposure to reveglucosidase alfa).
Pharmacokinetic analyses
Reveglucosidase alfa PK was evaluated (at day 1, week
12, and week 24) in all 3 dosing cohorts, using blood
samples taken before, during, and after infusions at pre-
dose, 1 h into infusion, 2 h into infusion, end of infusion
(EOI; time 0 for PK), and 0.25, 0.5, 1.0, 2.0, 3.0, 6.0, 12,
18, and 24 h post EOI.
Safety assessment
Infusion-related reactions were defined as adverse events
(AEs) occurring within 1 day after infusion. Assessments
included physical examinations and vital sign assess-
ments, pulse oximetry and blood glucose monitoring
before, during, and after infusions, AE recordings
(including signs of hypersensitivity and hypoglycemia),
chest X-rays, 12-lead echocardiograms, clinical labora-
tory assessments, and antibody testing (anti-reveglucosi-
dase alfa, anti-GAA, anti-insulin-like growth factor 1
[IGF1], and anti-IGF2). Serum IGF analytes (IGF1, IGF2,
and insulin-like growth factor-binding protein-3) were
measured to assess the effect of reveglucosidase alfa on
serum IGF levels. A subject who was clinically symptom-
atic or whose blood glucose level was <60 mg/dL was
treated as appropriate (oral and intravenous [IV]
dextrose). Subjects were measured every 15 min after
treatment for hypoglycemia until their blood glucose
reached >100 mg/dL.
Efficacy evaluation
The efficacy of reveglucosidase alfa was evaluated at
baseline and following 24 and 72 weeks of treatment.
Evaluations included mobility/endurance (6MWT),
respiratory muscle strength (maximum inspiratory pres-
sure [MIP], maximum expiratory pressure [MEP]), and
lung function tests (FVC-upright, FVC-supine, max-
imum voluntary ventilation [MVV]). Efficacy from the
20 mg/kg group is presented in this manuscript.
Data analysis
The extension phase (POM-002) has recently been com-
pleted. The data presented are from the 72-week interim
analysis. The efficacy analysis population consisted of all
subjects who were dosed with 20 mg/kg reveglucosidase
alfa. The safety analysis population consisted of all
subjects who enrolled into POM-001 and were dosed.
Safety analyses included a summary of AEs and im-
munogenicity. The statistical significance of treatment
effects was not determined as no pre-planned statistical
analyses were conducted for this study. Graphical dis-
plays were provided for efficacy endpoints.
Results
Study subjects
All enrolled subjects (N = 22) had a confirmed diagnosis
of LOPD based on 2 GAA gene mutations (see Additional
file 1) and were previously untreated with rhGAA. The
mean (range) % lower limit of normal GAA activity was
20.37 (5.5, 58.3). Subjects included in the intent-to-treat
population (Fig. 1) were administered reveglucosidase alfa
at initial doses of 5, 10, and 20 mg/kg, (n = 3, n = 3, n = 16,
respectively), every 2 weeks for 24 weeks. For the dose-
22 subjects enrolled
in dose escalation (weeks 1 to 24)  
5 mg/kg
n = 3
10 mg/kg
n = 3
20 mg/kg
n = 16
Completed
10 mg/kg
n = 2
Completed
5 mg/kg
n = 3
Completed
10 mg/kg
n = 3
Completed
20 mg/kg
n = 15
Withdrew
from 
the study
n = 1 
5 mg/kg
n = 3
10 mg/kg
n = 3
20 mg/kg
n = 15
Withdrew
from 
the study
n = 1 
21 subjects enrolled in
in dose extension (weeks 24 to 72)
19 subjects completed week 72
Completed
20 mg/kg
n = 14
Completed
5 mg/kg
n = 3
Withdrew
from 
the study
n = 1 
Fig. 1 Subject flow. Patient withdrawals during dose-escalation
(POM-001) and dose-extension (POM-002) were by physician decision
and subject decision, respectively
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escalation phase (POM-001), 21 subjects completed
24 weeks of dosing and enrolled in the extension study
(POM-002). In the first 72 weeks, 3 subjects withdrew
from the study because of a hypersensitivity AE (2 sub-
jects in the 20 mg/kg cohort and 1 in the 10 mg/kg
cohort). One subject in the 5 mg/kg cohort discontin-
ued treatment because of a hypersensitivity AE but
remained in the study. Eighteen subjects received reve-
glucosidase alfa (5, 10, or 20 mg/kg) every 2 weeks for
up to a total of 72 weeks. Demographics and baseline
characteristics (Table 1) describe a cohort of ambula-
tory LOPD subjects who had moderate respiratory
impairment (mean ± standard deviation [SD] percent
predicted FVC, 60.9 ± 19.2; MIP, 40.3 ± 24.0; and
MEP, 35.5 ± 14.4), with limitations for endurance seen
at baseline.
Pharmacokinetics
Reveglucosidase alfa was rapidly eliminated from
plasma with a mean terminal half-life (t½) of <1.2 h
post infusion for the 3 cohorts on day 1, week 12,
and week 24 (Table 2). Following 24 weeks of reve-
glucosidase alfa treatment, mean exposure by area
under the concentration-time curve (AUC) increased
by 18 and 23% in the 10 and 20 mg/kg arms respect-
ively, and mean exposure by AUC decreased by 30%
in the 5 mg/kg arm. Mean clearance (CL) values
ranged from 73.5–184 mL/h·kg in 10 and 20 mg/kg
subjects over the 24-week course of treatment and
demonstrated slight decreases (10 mg/kg, −22.4%;
20 mg/kg, −13.5%) from day 1 to week 24. Over the
24-week course of treatment in 5 mg/kg subjects,
mean t½ increased ≈2.0-fold, CL increased by 3.0-fold,
and volume in the terminal state and in steady state
increased 7.5- and 5.0-fold, respectively. Increases in
the mean values of AUC from 0 h and extrapolated
to infinity (AUC0-inf ) were greater than dose propor-
tional (>1:1) and dose linear (R2 > 0.99) on the 3 PK
evaluation days (day 1, week 12, and week 24), which
indicate exposure to reveglucosidase alfa is linear over
the 4.0-fold dose range (5–20 mg/kg) and over the
24 weeks of treatment (Fig. 2).
Safety and tolerability
In general, reveglucosidase alfa was reasonably tolerated
in all 22 subjects treated with 5 mg/kg, 10 mg/kg, or
20 mg/kg every other week. AEs that occurred in ≥10% of
the subjects are shown in Table 3. The most common AEs
were hypoglycemia (63%) and dizziness, fall, headache,
and nausea (55% for each). The majority of events were
mild or moderate in severity. Three subjects reported 6
events assessed as severe (grade 3) in the context of a
hypersensitivity event and included urticaria, rash, pruri-
tis, chest tightness, and allergic reaction. Three subjects
reported 4 events of symptomatic hypoglycemia including
3 events reported as severe and 1 reported as life-
threatening (grade 4). Other grade 3 events included ag-
gression, presyncope, and venous thrombosis, reported in
3 subjects. Six of the 22 subjects (27%) experienced 8 AEs
assessed as serious by the investigator. Of these, 5 were
assessed as related to the study drug and included
hypoglycemia (n = 2, 9%) and acute cardiac failure, hyper-
sensitivity, and presyncope (n = 1, 4.5% for each). The sub-
ject with acute cardiac failure was hospitalized overnight
for a protocol-mandated polysomnography. During the
hospital stay, a chest X-ray revealed pulmonary conges-
tion. Concurrent medical conditions included respiratory
failure and hypertension. The subject received furosemide,
and the event resolved the next day.
Hypoglycemia, a potential pharmacologic effect of the
IGF2 moiety of reveglucosidase alfa, was dose related.
AEs of hypoglycemia were reported in 0/3 (0%) subjects
receiving 5 mg/kg, 1/3 (33%) receiving 10 mg/kg, and
14/16 (88%) receiving 20 mg/kg. Hypoglycemia AEs
generally occurred intermittently during and/or within
2 h after the EOI and were managed with caloric supple-
mentation shortly after occurrence. Based on glucose
measures taken pre-infusion and up to 8 h post infusion,
the majority of the hypoglycemia AEs were reported as
grade 1 and 2, and were nonserious. Of the 15 subjects
who experienced a hypoglycemic AE, 2 subjects who
received 20 mg/kg reveglucosidase alfa each experienced
1 serious hypoglycemia AE. One subject experienced a
grade 3 serious AE of symptomatic hypoglycemia (blood
glucose, 36 mg/dL; diaphoresis, shaking, flushed, and
light headed), 3 h following initiation of the week 35
infusion of reveglucosidase alfa. Another subject
experienced a grade 4 serious AE of symptomatic
hypoglycemia (blood glucose, 29 mg/dL; clammy and
Table 1 Demographics and baseline characteristics
POM-001 (N = 22)
Mean age (range), years 49.3 (28–58)
Gender, n (%)
Male 14 (64)
Female 8 (36)
Mean weight (range), kg 89.0 (49.2–144.5)
Mean time since initial diagnosis (range), years 5.4 (0.106–25.12)
Mean % predicted MIP ± SD 40.3 ± 24.0
Mean % predicted MEP ± SD 35.5 ± 14.4
Mean MVV ± SD, L/min 68.9 ± 27.5
Mean % predicted FVC upright ± SD 60.9 ± 19.2
6MWT ± SD, meters 352.5 ± 151.1
Abbreviations:
6MWT 6-min walk test, FVC forced vital capacity, MEP maximal expiratory
pressure, MIP maximal inspiratory pressure, MVV maximum voluntary
ventilation, SD standard deviation
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sweaty, with blood pressure 75/40) occurred about an
hour following completion of the week 22 infusion of
reveglucosidase alfa. Both subjects had normal blood
glucose within 30 min following oral and IV dextrose.
Neither subject required hospitalization for the events,
and both continued treatment without dose modifica-
tion. No subjects in the study required dose modification
or discontinued treatment because of hypoglycemia.
Eleven of 22 subjects (50%) experienced at least one
hypersensitivity or anaphylaxis AE. The most common
hypersensitivity AEs were flushing (n = 5), urticaria (n = 5),
erythema (n = 4), and pruritic rash (n = 3). Chest discom-
fort (n = 5), flushing (n = 5), and hypotension (n = 3) were
the most common anaphylactic reactions. Seven of these
subjects had AEs consistent with the National Institute of
Allergy and Infectious Disease and the Food Allergy and
Anaphylaxis Network criteria of anaphylaxis. Of these 7
subjects, 2 had detectable anti-drug antibodies at one or
more time points through 72 weeks. Four subjects
discontinued treatment because of hypersensitivity or ana-
phylaxis. An additional 4 subjects required temporary
treatment interruption. Anaphylaxis or hypersensitivity
were managed with antihistamine or steroids and did not
require hospitalization.
All treated subjects tested positive for anti-
reveglucosidase alfa, anti-rhGAA, anti-IGF1, and anti-
IGF2 antibodies at least once during the first 72 weeks
of the study. The predominant antibody responses were
directed against reveglucosidase alfa and rhGAA with
mean (SD) therapeutic antibody (TAb) titers of 248,710
(344981) and 262,100 (409674), respectively, at study
week 72 in the 20 mg/kg cohort. Anti-reveglucosidase
alfa antibodies developed more slowly in the 5 mg/kg
cohort than the 10 and 20 mg/kg cohorts and the mean
(SD) titer for the 20 mg/kg cohort at week 24 was 1677
(2643) (see Additional file 2). TAb titers directed against
the GILT portion of reveglucosidase alfa were of much
lower titer, with a mean (SD) of 967 (2718) and 1300
(3565) for IGF1 and IGF2, respectively, at study week
72. Despite the development of antibodies against IGF1
and IGF2, no overall changes in plasma levels of IGF1 or
IGF2 were detected, and no sustained alterations in
blood glucose levels were observed. Although anti-
reveglucosidase alfa antibodies were detected in all 22
subjects, consistent associations between PK parameters
and antibody titers were not detected in the higher dose
cohorts. Efficacy and safety of reveglucosidase alfa were
not affected by the presence of antidrug antibodies
through 72 weeks.
Efficacy
Positive changes from baseline were observed from 6 to
72 weeks of treatment for efficacy endpoints (MIP, MEP,
Table 2 Reveglucosidase alfa mean (range) PK parameters in LOPD subjectsa
5 mg/kg 10 mg/kg 20 mg/kg
Day 1 Week 12 Week 24 Day 1 Week 12 Week 24 Day 1 Week 12 Week 24
Mean PK parameter (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) (n = 3) (n = 10) (n = 9) (n = 9)
Cmax (range),
ng/mL
28,172
(16072–
38,300)
28,829
(20072–
38,300)
14,117
(3084–
30,901)
80,873
(41225–
124,800)
49,843
(3235–
76,825)
55,187
(3451–100,440)
112,974
(59912–
250,500)
87,182
(25197–
171,780)
126,196
(53246–
218,400)
AUC0-inf (range),
ng·h/mL
32,004
(19865–
43,524)
34,411
(21470–
44,478)
22,343
(4587–
52,228)
109,655
(58114–
143,692)
90,439
(25777–
135,436)
129561b
(95030–
164,092)
294,648
(157200–
684,264)
261,255
(90854–
417,087)
361,068
(109285–
597,203)
Vz (range),
mL/kg
66.3
(46.0–105)
58.7
(38.5–90.6)
499
(42.3–1083)
98.4
(55.9–121)
442
(42.8–1154)
44.2b
(31.8–57.0)
76.6
(20.8–177)
95.5
(29.8–180)
92.2
(12.8–273)
CL (range),
mL/h·kg
173
(115–252)
160
(112–233)
558
(95.7–1090)
107
(69.6–172)
184
(73.8–388)
83.1b
(60.9–105)
84.9
(29.2–127)
101
(48.0–220)
73.5
(33.5–183)
Half-life (range),
hours
0.261
(0.217–0.289)
0.250
(0.237–0.270)
0.507
(0.306–0.688)
0.701
(0.475–1.07)
1.20
(0.327–2.06)
0.367b
(0.361–0.373)
0.723
(0.310–2.22)
0.715
(0.343–1.47)
0.767
(0.259–1.65)
Abbreviations:
AUC0-inf area under the concentration-time curve from 0 h extrapolated to infinity, CL clearance, Cmax minimum concentration, LOPD late-onset Pompe
disease, PK pharmacokinetics, Vz volume
aLOPD subject cohorts received 5 mg/kg (n = 3), 10 mg/kg (n = 3), or 20 mg/kg (n = 10 at week 1; n = 9 at week 24) of reveglucosidase alfa as a
weekly 2-h infusion for 24 weeks
bn = 2 for this parameter
0
50000
100000
150000
200000
250000
300000
350000
400000
Day 1 Week 12 Week 24
5 mg/kg 10 mg/kg 20 mg/kg
A
U
C
0-
in
f (
ng
·h
/m
L)
Fig. 2 Reveglucosidase alfa exposure-dose linearity over 24 weeks of
treatment. Exposure data presented as AUC0-inf on day 1, week 12,
and week 24 of dosing. Abbreviation: AUC0-inf, area under the
concentration-time curve from 0 h extrapolated to infinity
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FVC, 6MWT [Fig. 3] and MVV [see Additional file 3]).
The greatest efficacy gains were observed early in the
course of treatment with maximum improvements seen
by week 18, which were maintained over the course of
72 weeks. By week 24, reveglucosidase alfa treatment
increased from baseline subjects’ percent predicted MIP
(mean [SD], 11.1 [8.31] %, percent predicted MEP (5.2
[8.25] %), and MVV (2.3 [10.71] L/min) values and
increased the distance walked on the 6MWT (22.3
[54.23] m). This positive trend continued out to week 72
for MIP, MEP, and MVV, with mean (SD) changes from
baseline of 13.9 (20.23) %, 8.0 (15.18) %, and 7.4 (25.44)
L/min, respectively. At week 72, 12/14 subjects had
maintained improvement in MIP (Fig. 4), indicating that
MIP was increased in most subjects. In contrast, percent
predicted FVC remained relatively unchanged over the
Table 3 Adverse events occurring in ≥10% LOPD subjects
Subjects with any AE, n (%)a 5 mg/kg (N = 3) 10 mg/kg (N = 3) 20 mg/kg (N = 16) Total (N = 22)
Hypoglycemia 0 (0) 1 (33) 14 (88) 15 (68)
Dizziness 1 (33) 1 (33) 10 (63) 12 (55)
Fall 3 (100) 3 (100) 6 (38) 12 (55)
Headache 2 (67) 2 (67) 8 (50) 12 (55)
Nausea 1 (33) 1 (33) 10 (63) 12 (55)
Fatigue 2 (67) 1 (33) 7 (44) 10 (45)
Chest discomfort 2 (67) 1 (33) 6 (38) 9 (41)
Vomiting 1 (33) 1 (33) 6 (38) 8 (36)
Dyspnea 0 (0) 1 (33) 6 (38) 7 (32)
Malaise 1 (33) 0 (0) 6 (38) 7 (32)
Chills 0 (0) 1 (33) 5 (31) 6 (27)
Nervousness 1 (33) 0 (0) 5 (31) 6 (27)
Tachycardia 0 (0) 1 (33) 8 (50) 6 (27)
Abdominal pain upper 1 (33) 0 (0) 4 (25) 5 (23)
Feeling hot 0 (0) 1 (33) 4 (25) 5 (23)
Flushing 1 (33) 0 (0) 4 (25) 5 (23)
Rash 1 (33) 0 (0) 4 (25) 5 (23)
Urticaria 1 (33) 1 (33) 3 (19) 5 (23)
Cold sweat 0 (0) 0 (0) 4 (25) 4 (18)
Erythema 1 (33) 0 (0) 3 (19) 4 (18)
Feeling cold 0 (0) 1 (33) 3 (19) 4 (18)
Hyperhidrosis 0 (0) 0 (0) 4 (25) 4 (18)
Hypertension 0 (0) 0 (0) 4 (25) 4 (18)
Hypotension 0 (0) 0 (0) 4 (25) 4 (18)
Edema peripheral 0 (0) 0 (0) 3 (19) 3 (14)
Hot flush 1 (33) 0 (0) 2 (13) 3 (14)
Infusion-related reaction 2 (67) 0 (0) 1 (6) 3 (14)
Pallor 0 (0) 0 (0) 3 (19) 3 (14)
Pruritus 0 (0) 0 (0) 3 (19) 3 (14)
Rash pruritic 1 (33) 1 (33) 1 (6) 3 (14)
Tremor 0 (0) 0 (0) 3 (19) 3 (14)
Subjects with any serious AE, n (%)
Hypoglycemia 0 (0) 0 (0) 2 (13) 2 (9)
Acute cardiac failure 0 (0) 0 (0) 1 (6) 1 (5)
Hypersensitivity 0 (0) 0 (0) 1 (6) 1 (5)
Presyncope 0 (0) 0 (0) 1 (6) 1 (5)
Abbreviations:
AE adverse event, LOPD late-onset Pompe disease
aAll 22 subjects reported ≥1 AE
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course of the 72-week treatment (Fig. 3c). Results of the
6MWT for 20 mg/kg subjects were positive throughout
the treatment duration (Fig. 3d), with a change of 24.5
(SD, 62.8) meters in mean absolute distance walked at
week 72 compared with baseline.
Discussion
LOPD is a rare genetic neuromuscular disorder caused
by GAA deficiency, ultimately resulting in the loss of
mobility and respiratory failure. Current ERT with
rhGAA has limited efficacy in LOPD subjects partly
because of inefficient delivery of rhGAA to skeletal
muscle lysosomes and the impact of GAA deficiency in
the CNS [22]. Reveglucosidase alfa is a novel rhGAA
analogue with both improved lysosomal uptake [23] and
glycogen reduction in skeletal muscle [19]. In this phase
1/2 study, we evaluated the PK, safety, tolerability, and
efficacy of reveglucosidase alfa in ambulatory LOPD
subjects who were previously untreated with rhGAA.
Our results show that reveglucosidase alfa infusions
were reasonably tolerated and resulted in improvement
of respiratory muscle strength, and ventilatory func-
tion, however there was a limited effect on walking
endurance.
The PK profile of reveglucosidase alfa is consistent
with enhanced uptake of the enzyme into tissue. Reve-
glucosidase alfa contains a lysosomal-targeting peptide
[23] that binds with high affinity to the CI-MPR, the
receptor that mediates uptake of rhGAA into skeletal
muscle lysosomes [9, 12, 13]. The short half-life and
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high CL of reveglucosidase alfa indicates a rapid distri-
bution and suggests enhanced Cl-MPR–mediated uptake
of the enzyme into tissue.
As expected, subjects developed antibodies against
reveglucosidase alfa, although no impact on efficacy or
safety was observed through 24 weeks. While high thera-
peutic antibody titers were evident at week 72, less than
20% of subjects were positive for neutralizing antibody
at any time point. Moreover, despite the development of
anti-IGF-IR neutralizing antibodies, overall changes in
IGF-I levels were not detected in the study. Patients
treated with the rhGAA alglucosidase alfa (Myozyme®;
Genzyme, Cambridge, MA, USA) also develop anti-
bodies [10, 24–27], which can block the delivery of the
recombinant enzyme in tissues such as muscle and re-
sult in attenuated efficacy of Myozyme [28, 29]. Subjects
treated with reveglucosidase alfa who have persistently
high antibody titers would require close monitoring for
efficacy and safety until the effects of the antibodies are
more fully understood [13, 30].
To determine the efficacy of reveglucosidase alfa,
established measures of respiratory muscle strength
(MIP and MEP), lung capacity (FVC and MVV), and
mobility (6MWT) were utilized [10, 27]. In particular,
MIP and MEP are sensitive measures of respiratory
muscle strength in patients with neuromuscular dis-
eases [31–34] and correlate with more direct measures
of diaphragmatic muscle strength. Additionally, a sys-
tematic literature review examining 174 patients with
LOPD from 34 studies demonstrated that pulmonary
function tests predicted ventilator use [35]. In particu-
lar, MIP and upright vital capacity consistently corre-
lated with ventilation and wheelchair use. The current
study demonstrated that reveglucosidase alfa improved
MIP, MEP, MVV, and 6MWT by 24 weeks of treatment,
and these improvements were maintained for >1 year
of treatment, with stable lung volumes as assessed by
FVC throughout the study duration. The higher gains
in MIP compared with FVC may be related to changes
in muscle strength occurring prior to gains in volume,
in addition to potential limitations in lung volume
expansion related to scoliosis and lung elasticity in
neuromuscular disease [36]. The impact of scoliosis,
which is common in LOPD [37], is known to contribute
to extrapulmonary restrictive lung disease [38, 39]. The
frequency or degree of spinal abnormalities was not
evaluated in the current study.
Evaluation of the long-term benefit of reveglucosidase
alfa requires accurate knowledge of the rate of disease
progression in untreated patients. The natural history of
LOPD suggests that respiratory muscle strength, lung
capacity, and walking endurance steadily decrease at
rates of 1–4% per year [1, 5, 10, 40]. van der Beek et al.
[40], for example, reported annual declines in FVC
(−1.1%), MIP (−3.2%), and MEP (−3.8%). The fact that
reveglucosidase alfa increased respiratory muscle
strength, lung capacity, and walking endurance (by as
much as 13.9% for up to 72 weeks of treatment) suggests
that reveglucosidase alfa has an initial effect on the dis-
ease. Longer term studies, however, are needed to deter-
mine whether reveglucosidase alfa impacts disease
progression in patients with LOPD.
Given the serious clinical consequences of progressive
LOPD (eg, respiratory failure and mobility loss) and
other neuromuscular diseases, the benefit:risk ratio of an
ERT is important to consider. In this study, a favorable
benefit:risk ratio is suggested by improvements in global
respiratory muscle strength and a reasonable AE profile.
Although hypersensitivity-type reactions are a serious
potential complication of any recombinant human pro-
tein [41], these events were manageable with antihista-
mines or steroids and did not require hospitalization.
Hypoglycemia occurred intermittently, was mostly mild
and successfully managed in all subjects using caloric
supplementation shortly after each occurrence, and did
not result in dose reduction or discontinuation. The
reduced plasma glucose in some subjects reflects a
pharmacologic effect of IGF2 derived from the GILT tag
of reveglucosidase alfa [23].
Conclusions
Additional studies are needed to further assess the safety
and efficacy of this approach. Improvements in respira-
tory muscle strength, lung function, and walking endur-
ance in subjects with LOPD may outbalance the risk of
hypersensitivity reactions and hypoglycemia. These
findings suggest that reveglucosidase alfa may provide a
potential new treatment option for patients with LOPD.
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